Givinostat (Duvyzat) for Duchenne Muscular Dystrophy
Givinostat (Duvyzat) for Duchenne Muscular Dystrophy
December 23, 2024 (Issue: 1718)
Givinostat (Duvyzat – Italfarmaco), an oral histone
deacetylase inhibitor, has been approved by the FDA
for treatment of patients ≥6 years old with Duchenne
muscular dystrophy (DMD), regardless of the DMD-causing
mutation. It is the first...more
- Deflazacort (Emflaza) for Duchenne muscular dystrophy. Med Lett Drugs Ther 2017; 59:153.
- Vamorolone (Agamree) for Duchenne muscular dystrophy. Med Lett Drugs Ther 2024 May 28 (epub).
- F Fortunato et al. Innovative therapeutic approaches for Duchenne muscular dystrophy. J Clin Med 2021; 10:820. doi:10.3390/jcm10040820
- M Rodrigues and T Yokota. An overview of recent advances and clinical applications of exon skipping and splice modulation for muscular dystrophy and various genetic diseases. Methods Mol Biol 2018; 1828:31. doi:10.1007/978-1-4939-8651-4_2
- Eteplirsen (Exondys 51) for Duchenne muscular dystrophy. Med Lett Drugs Ther 2016; 58:145.
- Golodirsen (Vyondys 53) for Duchenne muscular dystrophy. Med Lett Drugs Ther 2020; 62:119.
- Viltolarsen (Viltepso) for Duchenne muscular dystrophy. Med Lett Drugs Ther 2020; 62:167.
- Casimersen (Amondys 45) for Duchenne muscular dystrophy. Med Lett Drugs Ther 2021; 63:e104.
- PR Clemens et al. Efficacy and safety of viltolarsen in boys with Duchenne muscular dystrophy: results from the phase 2, open-label, 4-year extension study. J Neuromuscul Dis 2023; 10:439. doi:10.3233/jnd-221656
- J Iff et al. Survival among patients receiving eteplirsen for up to 8 years for the treatment of Duchenne muscular dystrophy and contextualization with natural history controls. Muscle Nerve 2024 March 14 (epub). doi:10.1002/mus.28075
- JR Mendell et al. Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy. Front Cell Dev Biol 2023; 11:1167762. doi:10.3389/fcell.2023.1167762
- C Mozzetta et al. HDAC inhibitors as pharmacological treatment for Duchenne muscular dystrophy: a discovery journey from bench to patients. Trends Mol Med 2024; 30:278. doi:10.1016/j.molmed.2024.01.007
- E Mercuri et al. Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2024; 23:393. doi:10.1016/s1474-4422(24)00036-x
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2023 January 25 (epub). Available at: www.medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- RL Woosley et al. QTdrugs list. Available at: www.crediblemeds.org. Accessed December 5, 2024.
- Approximate WAC. WAC = wholesaler acquisition cost or manufacturer’s published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. December 5, 2024. Reprinted with permission by First Databank, Inc. All rights reserved. ©2024. www.fdbhealth.com/policies/drug-pricing-policy.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Givinostat (Duvyzat) for Duchenne Muscular Dystrophy
Article code: 1718c
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
